Natriuretic peptides and right atrial fibrosis in patients with paroxysmal versus persistent atrial fibrillation

Peptides

Volumn 31, Issue 8, 2010, Pages 1531-1539

  Cao, Hailong ^a   Xue, Lei ^a   Wu, Yanhu ^a   Ma, Hongtai ^a   Chen, Liang ^a   Wang, Xiaowei ^a   Zhu, Quan ^a   Dai, Ninghuang ^b   Chen, Yijiang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Atrial fibrillation; Atrial fibrosis; Natriuretic peptides; Valvular replacement

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; FEMALE; FIBROSIS; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SINUS RHYTHM;

EID: 78249274877     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.04.019     Document Type: Article

References (34)

1. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90:400-405
2. Brundel BJ, Henning RH, Ke L, van Gelder IC, Crijns HJ, Kampinga HH. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006; 41: 555-562
3. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343:246-253
4. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31:7-18.
5. Dorrington KL. A role for natriuretic peptides as well as endothelins in the hypoxic lungs of patients with chronic obstructive pulmonary disease. Respiration 1999; 66:208-209
6. Doyama K, Fukumoto M, Takemura G, Tanaka M, Oda T, Hasegawa K, et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol 1998; 32:1832-1838
7. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669-1677
8. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J 2006; 27:1648-1650
9. Grammer JB, Böhm J, Dufour A, Benz M, Lange R, Bauernschmitt R. Atrial fibrosis in heart surgery patients. Decreased collagen III/I ratio in postoperative atrial fibrillation. Basic Res Cardiol 2005; 100:288-294
10. Gray RJ, Helfant RH. Timing of surgery in valvular heart disease. Cardiovasc Clin 1993; 23:209-231
11. Hammerer-Lercher A, Neubauer E, Müller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001; 310:193-197
12. Hildebrandt P, Richards AM. Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2008; 101:21-24
13. Iida H, Shibata Y. Phasic secretion of newly synthesized atrial natriuretic factor from unstimulated atrial myocytes in culture. Circ Res 1994; 74:659-668
14. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6:92-96
15. Kaji Y, Miyoshi T, Doi M, Hirohata S, Kamikawa S, Sakane K, et al. Augmentation index is associated with B-type natriuretic peptide in patients with paroxysmal atrial fibrillation. Hypertens Res 2009; 32:611-616
16. Liu H, Qu X, Liang Z, Chen W, Xia W, Song Y. Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs. Biochem Biophys Res Commun 2008; 377:884-888
17. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Nishimura T, Yamada H, et al. Low dose synthetichumanatrial natriuretic peptide infusion in a patient with mitral stenosis and severe pulmonary hypertension. Jpn Circ J 1999; 63:816-818
18. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi Jr JL. Biology of the natriuretic peptides. Am J Cardiol 2008; 101:3-8.
19. Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009; 53:1783-1790
20. Möllmann H, Weber M, Elsässer A, Nef H, Dill T, Rixe J, et al. NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J 2008; 72:921-925
21. Nakamura M, Niinuma H, Chiba M, Ueshima K, Arakawa N, Yagi Y, et al. Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. Am J Cardiol 1997; 79:966-970
22. Omland T, de Lemos JA. Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart disease. Am J Cardiol 2008; 101:61-66
23. Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006; 47:2141-2151
24. Potocki M, Mair J, Weber M, Hamm C, Burkard T, Hiemetzberger R, et al. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation. Am J Cardiol 2009; 104:559-564
25. Pucci A, Wharton J, Arbustini E, Grasso M, Diegoli M, Needleman P, et al. Localization of brain and atrial natriuretic peptide in human and porcine heart. Int J Cardiol 1992; 34:237-247
26. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjørnerheim R, Endresen K, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142:725-732
27. Razzolini R, Leoni L, Cafiero F, Liva S, Faggian D, Ramondo A, et al. Neurohormones in mitral stenosis before and after percutaneous balloon mitral valvotomy. J Heart Valve Dis 2002; 11:185-190
28. Roy D, Paillard F, Cassidy D, Bourassa MG, Gutkowska J, Genest J, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol 1987; 9:509-514
29. Shimamura K, Kajimoto K. Acute efficacy of low-dose human atrial natriuretic peptide monotherapy without loop diuretics for acute decompensated heart failure with left ventricular systolic dysfunction: a case report. Int J Cardiol 2009; (January) [Epub ahead of print].
30. Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van Den Berg MP, Driessen C, et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10:827-835
31. Vinch CS, Rashkin J, Logsetty G, Tighe DA, Hill JC, Meyer TE, et al. Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm. Cardiology 2004; 102:188-193
32. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88:1004-1009
33. Wozakowska-Kaplon B, Opolski G, Janion M, Kosior D. Plasma concentration of atrial natriuretic peptide is related to the duration of atrial fibrillation in patients with advanced heart failure. Kardiol Pol 2004; 61:513-517
34. Yoshihara F, Nishikimi T, Sasako Y, Hino J, Kobayashi J, Minatoya K, et al. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure. J Am Coll Cardiol 2002; 39:288-294